Logo

ECL

Ecolab Inc.

ECL

Ecolab Inc. NYSE
$275.16 0.06% (+0.17)

Market Cap $78.00 B
52w High $286.04
52w Low $221.62
Dividend Yield 2.60%
P/E 39.53
Volume 604.01K
Outstanding Shares 283.47M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $4.165B $1.105B $585M 14.046% $2.06 $789M
Q2-2025 $4.025B $1.092B $524.2M 13.023% $1.85 $977.8M
Q1-2025 $3.695B $1.051B $402.5M 10.893% $1.42 $818.2M
Q4-2024 $4.005B $1.052B $472.9M 11.807% $1.67 $848.5M
Q3-2024 $3.998B $1.028B $736.5M 18.419% $2.6 $1.303B

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.956B $23.898B $14.144B $9.719B
Q2-2025 $1.921B $23.736B $14.385B $9.32B
Q1-2025 $1.163B $22.366B $13.463B $8.876B
Q4-2024 $1.257B $22.388B $13.599B $8.757B
Q3-2024 $1.261B $22.102B $13.526B $8.548B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $589.7M $791.3M $-280.6M $-477.4M $34.9M $529.7M
Q2-2025 $528.5M $701.8M $-224.4M $297.3M $758.3M $485.1M
Q1-2025 $406.5M $369.4M $-224M $-241.6M $-94.2M $131.5M
Q4-2024 $492.4M $766.7M $-627.5M $-140.1M $-4.3M $407M
Q3-2024 $736.5M $786.7M $639.1M $-548.3M $877.1M $550.3M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Global Institutional and Specialty
Global Institutional and Specialty
$1.37Bn $1.42Bn $1.54Bn $1.59Bn
Global Life Sciences
Global Life Sciences
$0 $170.00M $190.00M $180.00M
Global Pest Elimination
Global Pest Elimination
$300.00M $280.00M $320.00M $330.00M
Global Water
Global Water
$0 $1.83Bn $1.98Bn $2.05Bn
Global Healthcare and Life Sciences
Global Healthcare and Life Sciences
$320.00M $0 $0 $0
Global Industrial
Global Industrial
$2.07Bn $0 $0 $0

Five-Year Company Overview

Income Statement

Income Statement Over the past five years, Ecolab’s sales have grown steadily, and profitability has recovered well from the disruption of 2020. Gross profit and operating profit have both trended upward, suggesting the company has been able to pass through price increases, manage costs, and benefit from scale. Earnings dipped during the pandemic and inflation spike but have since rebounded strongly, with margins now noticeably healthier than a few years ago. The main story in the income statement is consistent growth plus improving efficiency, although results still depend on industrial and service activity across many end markets.


Balance Sheet

Balance Sheet Ecolab’s balance sheet shows a larger business than five years ago, with total assets and shareholders’ equity both growing. Debt climbed during the early part of the period and has since edged down, but leverage remains meaningful rather than minimal, so interest costs and credit markets still matter. Cash levels are adequate but not excessive, indicating a balanced approach between liquidity and reinvestment. Overall, the company looks financially solid, but it is not a low-debt, cash-heavy balance sheet; discipline around debt and funding costs remains an important watchpoint.


Cash Flow

Cash Flow Cash generation has strengthened alongside the earnings recovery. Operating cash flow has improved over time, and after funding higher but still manageable capital spending, Ecolab regularly produces a solid stream of free cash flow. This suggests that reported profits are generally backed by real cash and that the business can support investment, debt service, and shareholder returns without stretching itself. The trend points to better cash efficiency than a few years ago, though continued investment is required to support growth and innovation.


Competitive Edge

Competitive Edge Ecolab holds a strong position as a global leader in water, hygiene, and infection prevention solutions. Its edge comes from a mix of proprietary chemistry, digital monitoring platforms, and a very large on-site service workforce that embeds Ecolab deeply in customer operations. Once installed, its systems and programs can be difficult and costly for customers to replace, creating high switching costs. Its scale and global reach also allow it to serve multinational clients consistently across many countries. The main competitive risks are ongoing rivalry from other specialty chemical and service providers, pricing pressure in more commoditized areas, and the need to keep its technology and service levels clearly ahead of peers.


Innovation and R&D

Innovation and R&D Innovation is a clear pillar of Ecolab’s strategy. The company blends advanced chemistry with digital tools such as its ECOLAB3D and 3D TRASAR platforms, which use sensors, data analytics, and automation to optimize water, energy, and cleaning processes in real time. It is pushing into AI-enabled solutions, digital twins for industrial systems, and specialized offerings for fast-growing areas like data centers and life sciences. Programs like Ecolab Science Certified and Water for Climate show a strong tilt toward sustainability and public health, which aligns with long-term customer and regulatory trends. The main execution risk is that these innovations must keep delivering measurable value to customers to justify premium pricing and maintain Ecolab’s technology lead.


Summary

Taken together, Ecolab looks like a mature, steadily growing industrial solutions company with an improving earnings profile, a solid but leveraged balance sheet, and strong cash generation. Its deep customer integration, service-heavy model, and proprietary digital platforms create a durable competitive position, while its focus on water, energy efficiency, and hygiene aligns with global sustainability and regulatory tailwinds. Key things to watch include how well it manages its debt load in a changing interest-rate environment, its ability to sustain margin gains if economic conditions soften, and the continued success of its innovation efforts in high-growth areas such as life sciences, data centers, and advanced digital solutions.